Here’s why Emergent BioSolutions is worth investing!
Emergent BioSolutions, Inc. (NYSE: EBS), a life sciences company is developing a portfolio of vaccines and therapeutics for urgent health threats, announced the acceptance of a Biologics License Application (BLA) for AV7909 (Anthrax Vaccine Adsorbed, Adjuvanted) by the U.S. Food and Drug Administration (FDA). The...
